Results 111 to 120 of about 9,430 (168)

Noninfectious uveitis: Management with biologic agents. [PDF]

Indian J Ophthalmol
Rathinam SR, Anjana S.
europepmc   +1 more source

Cost-Effectiveness Analysis of Etrasimod Compared With Biologic Therapies for the Treatment of Patients with Moderately-to-Severely Active Ulcerative Colitis in Spain. [PDF]

Pharmacoecon Open
Rodríguez-Lago I, Muñoz Núñez F, Lucendo AJ, De Lossada Juste A, Cabez A, de la Cuadra-Grande A, Oyagüez I, Monte-Boquet E.   +7 more
europepmc   +1 more source

Treat-to-Target Monitoring Adherence and Rates of Healthcare Utilization in Patients With Inflammatory Bowel Disease in a Regional Healthcare System. [PDF]

Clin Transl Gastroenterol
Haydek JP, Mohan R, Lew J, Oonk A, Cheng D, Ahmed W, Click B, Fennimore B, Gerich M, Patel SG, Wani S, Hou JK, Scott FI.   +12 more
europepmc   +1 more source

Safety profile of TNF- alpha Inhibitors in pediatric patients: A post-marketing surveillance study based on the FAERS database. [PDF]

PLoS One
Yang Y, Wang P, Li QX.
europepmc   +1 more source

Analysis of Onset Timing and Risk Factors for Mesalazine-related Adverse Events Using the JADER Database. [PDF]

In Vivo
Iwayama K, Manabe T, Arai Y, Wakata Y, Oikawa G, Yamamoto M, Soma M, Ohtaki KI, Konda A, Machida M.   +9 more
europepmc   +1 more source

Developing models for the diagnosing of ulcerative colitis and prognosis of anti-TNF-α non-response based on neutrophil extracellular trap-associated genes. [PDF]

Front Immunol
Ou J, Li L, Zhi F, Huang B, Zhao X.
europepmc   +1 more source

Perioperative biologic use and postoperative outcomes in patients with inflammatory arthritis: a systematic review. [PDF]

BMC Rheumatol
Brady S, Taylor J, Carlisle K, Adamson J, Fulbright H, Hewitt C, Mandefield L, Mankia K, Pandit H, Mott A.   +9 more
europepmc   +1 more source

Risk factors and prevalence of latent tuberculosis infection in rheumatic patients: a meta-analysis. [PDF]

BMC Infect Dis
Huang J, Xia J, Hong B, Zhang C, Zhao L, Yuan P, Jiang S.   +6 more
europepmc   +1 more source

Adoption of new treatment options in non-systemic juvenile idiopathic arthritis (JIA) in clinical practice. [PDF]

Pediatr Rheumatol Online J
Lamers HC, Van Nieuwenhove E, Vastert SJ, Jansen MHA, van Royen-Kerkhof A, Swart JF, de Roock S.   +6 more
europepmc   +1 more source

Infective pneumonia following the use of tumor necrosis factor-α inhibitors in inflammatory bowel disease patients: A real-world disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database. [PDF]

PLoS One
Tang Q, Tang X, Yin W, Li Y, Zhong X.
europepmc   +1 more source